Mirum's Livmarli meets Phase III goal in ultra-rare liver diseases

Mirum's Livmarli meets Phase III goal in ultra-rare liver diseases: the analysis positions MIRM, TAK and NTRA to benefit and ALNY, INCY and VRTX under pressure; confidence high.

Analyzed 2026-10-13 — point-in-time, never revised. Outcomes are scored against SPY and published either way.

Ranked exposures

  1. ▲ MIRM Mirum — impact +88 · confidence high · horizon immediate · 1st order
    Livmarli's successful Phase III results expand its label and increase Mirum's prescription revenue.
    Chain: Phase III EXPAND meets primary endpoint → label expansion filed for additional cholestatic diseases → eligible patient pool widens in United States → Livmarli prescription volume and net revenue rise
    What would break the call: FDA rejects the supplemental filing or demands a confirmatory study, delaying label expansion past next year.
  2. ▲ TAK Takeda — impact +26 · confidence medium · horizon quarters · 2nd order
    Broader Livmarli approval directly increases Takeda's royalty income under its maralixibat license.
    Chain: Livmarli label expands after positive trial → Mirum sales of maralixibat increase → royalty rate applies to higher net sales → Takeda collects larger licensing income
    What would break the call: Mirum buys out the royalty obligation in a lump sum, ending the ongoing revenue stream.
  3. ▼ ALNY Alnylam — impact -25 · confidence low · horizon quarters · 3rd order
    Alnylam reduces pipeline investment after Livmarli success shrinks the pool of untreated patients with rare liver diseases.
    Chain: approved oral therapy covers more cholestatic patients → untreated rare liver population shrinks → competing pipeline programs face smaller commercial opportunity → Alnylam liver program economics look weaker
    What would break the call: Alnylam reports data in a genetically distinct liver indication that Livmarli does not address.
  4. ▲ NTRA Natera — impact +25 · confidence low · horizon weeks · 3rd order
    Natera drives higher test volume when diagnosis improves for patients eligible to receive Livmarli in ultra-rare liver diseases.
    Chain: new treatment option raises diagnostic urgency → physicians order more genetic panels for cholestasis → testing volume rises at specialty labs → Natera revenue per genetic test grows
    What would break the call: Screening stays confined to existing referral centers, leaving genetic test volumes flat.
  5. ▲ ILMN Illumina — impact +20 · confidence low · horizon weeks · 3rd order
    Illumina increases instrument sales as more patients undergo genetic testing to qualify for Livmarli therapy in rare diseases.
    Chain: treatable rare liver disease spurs sequencing demand → clinical labs run more exome and panel tests → consumables and instrument orders increase → Illumina sequencing revenue ticks higher
    What would break the call: Clinical labs absorb extra tests on existing capacity, producing no new instrument or consumable orders.
  6. ▼ INCY Incyte — impact -16 · confidence low · horizon quarters · 2nd order
    Incyte faces a higher efficacy bar and a smaller untreated population for its acquired cholestatic pruritus candidate.
    Chain: Livmarli sets efficacy benchmark in cholestatic pruritus → regulators expect comparable or better itch reduction → Incyte candidate faces tougher trial design → commercial opportunity narrows for late entrant
    What would break the call: Incyte's candidate posts superior itch data in a population where Livmarli failed.
  7. ▲ RARE Ultragenyx — impact +16 · confidence low · horizon quarters · 3rd order
    Ultragenyx runs liver-directed rare disease programs, and validated regulatory pathways for tiny pediatric populations shorten its development timelines.
    Chain: regulator accepts endpoints in tiny pediatric populations → precedent lowers development uncertainty for peers → Ultragenyx liver programs reuse that pathway → expected approval timelines and costs improve
    What would break the call: FDA demands different endpoints for Ultragenyx programs, removing the read-across from the EXPAND design.
  8. ▼ VRTX Vertex — impact -15 · confidence low · horizon quarters · 3rd order
    Vertex sees lower clinical trial recruitment after patients choose Livmarli for treatment of ultra-rare liver diseases.
    Chain: approved therapy available in rare liver disease → eligible patients prefer treatment over randomization → competing trials recruit more slowly → Vertex liver program timelines extend
    What would break the call: Vertex enrollment completes on schedule, showing no competition for patients from Livmarli uptake.
  9. ▲ MDGL Madrigal Pharmaceuticals — impact +15 · confidence low · horizon immediate · 3rd order
    Investor appetite for liver disease specialists rises after a clean Phase III readout validates the hepatology commercial model.
    Chain: positive liver trial lifts hepatology sentiment → investors reprice liver focused specialty names → Madrigal valuation multiple benefits → cost of equity capital falls
    What would break the call: Madrigal reports weak quarterly Rezdiffra scripts, overwhelming any sector sentiment benefit.
  10. ▲ QGEN Qiagen — impact +15 · confidence low · horizon weeks · 3rd order
    Qiagen expands its diagnostic revenue after screening for ultra-rare liver diseases increases due to new therapy.
    Chain: treatable indication increases diagnostic testing demand → labs expand cholestatic and hepatic panels → sample prep and assay kit sales rise → Qiagen consumables revenue grows modestly
    What would break the call: Rare liver screening volumes stay flat because diagnosis already occurs through existing clinical pathways.
  11. ▲ TVTX Travere Therapeutics — impact +14 · confidence low · horizon quarters · 2nd order
    Travere earns contingent milestones tied to the bile acid portfolio it sold to Mirum, and stronger commercial execution accelerates payments.
    Chain: Mirum acquired bile acid assets from Travere → contingent milestones tied to approvals and sales → EXPAND success triggers regulatory and commercial milestones → Travere receives cash payments
    What would break the call: Milestone terms cover only indications already approved, so EXPAND triggers no additional payment.
  12. ▼ GILD Gilead — impact -12 · confidence low · horizon quarters · 2nd order
    Gilead meets tougher competition for Livdelzi as bile acid transport inhibitors advance into adult cholestatic liver indications.
    Chain: IBAT inhibitors validated in cholestatic liver disease → developers push into adult cholestatic indications → Livdelzi faces added competitive pressure → Gilead pricing and share assumptions soften
    What would break the call: Maralixibat data stays confined to pediatric indications with no adult cholestatic development program announced.
  13. ▲ XBI SPDR S&P Biotech ETF — impact +12 · confidence low · horizon immediate · 3rd order
    A successful rare disease Phase III lifts small cap biotech risk appetite and supports the index of development stage names.
    Chain: Phase III success in ultra-rare indication → risk appetite for small cap biotech improves → fund flows into the sector increase → XBI constituents rally together
    What would break the call: A rate shock or a large clinical failure elsewhere resets biotech risk appetite lower.
  14. ▼ CI Cigna — impact -10 · confidence low · horizon quarters · 2nd order
    Express Scripts pays claims on expanded ultra-rare therapy volume, lifting pharmacy cost before client pricing resets.
    Chain: label expansion enlarges eligible population → Express Scripts adjudicates more six-figure claims → pharmacy benefit cost per member rises → client repricing lags the cost increase
    What would break the call: Express Scripts negotiates a rebate that fully offsets the incremental net cost per patient.
  15. ▲ COR Cencora — impact +10 · confidence low · horizon quarters · 2nd order
    Cencora distributes ultra-rare specialty drugs and earns fee-for-service margin on each additional Livmarli shipment to pediatric liver centers.
    Chain: Livmarli unit volumes rise after label expansion → specialty distribution handles additional shipments → fee-for-service revenue accrues per unit handled → Cencora specialty segment income rises slightly
    What would break the call: Mirum shifts to direct distribution or a single exclusive pharmacy, bypassing Cencora handling fees.
  16. ▼ TMDX TransMedics — impact -9 · confidence low · horizon quarters · 3rd order
    Fewer pediatric liver transplants reduce case volume for organ perfusion systems when effective medical therapy delays listing.
    Chain: effective medical therapy slows cholestatic disease progression → fewer children progress to liver transplant listing → pediatric liver transplant case volume declines → TransMedics liver perfusion case count softens
    What would break the call: National liver transplant volumes keep rising on adult indications, leaving TransMedics case growth unaffected.
  17. ▲ MCK McKesson — impact +9 · confidence low · horizon quarters · 2nd order
    McKesson specialty distribution and pharmacy units capture handling fees as Livmarli volumes grow across new cholestatic patient populations.
    Chain: Livmarli prescriptions grow across new indications → specialty distribution and pharmacy units handle volume → handling and dispensing fees increase → McKesson specialty segment revenue rises marginally
    What would break the call: Mirum awards exclusive distribution to a rival specialty network, excluding McKesson from the channel.
  18. ▼ CNC Centene — impact -8 · confidence low · horizon quarters · 2nd order
    Centene carries heavy Medicaid exposure to pediatric rare disease costs, and more treated children raise its drug spending.
    Chain: more pediatric patients qualify for expensive therapy → Medicaid covers most pediatric rare disease cases → Centene pharmacy claims cost increases → medical loss ratio rises at the margin
    What would break the call: State Medicaid programs carve rare disease drugs out of managed care capitation, shifting cost to the state.
  19. ▲ CVS CVS Health — impact +8 · confidence low · horizon quarters · 2nd order
    Specialty pharmacy dispensing adds revenue per filled Livmarli prescription because limited distribution networks concentrate these ultra-rare scripts.
    Chain: limited distribution network concentrates ultra-rare scripts → CVS specialty pharmacy dispenses the drug → revenue and dispensing fees accrue per fill → specialty pharmacy segment revenue grows
    What would break the call: Mirum names a different exclusive specialty pharmacy, removing CVS from the dispensing channel.
  20. ▲ IQV IQVIA — impact +8 · confidence low · horizon quarters · 3rd order
    IQVIA books service revenue from rare disease trial operations as sponsors fund registries and confirmatory pediatric liver studies.
    Chain: approval drives confirmatory and registry commitments → sponsors fund post-marketing rare disease studies → contract research demand increases → IQVIA service backlog and revenue grow
    What would break the call: Mirum runs registry and post-marketing work in house with a different contract research partner.
  21. ▼ ELV Elevance Health — impact -7 · confidence low · horizon quarters · 2nd order
    Elevance absorbs higher specialty outlays as additional ultra-rare liver patients qualify for six-figure annual therapy.
    Chain: label expansion enlarges eligible patient population → commercial and Medicaid plans must cover therapy → specialty pharmacy claims cost rises → Elevance medical loss ratio widens slightly
    What would break the call: Elevance negotiates outcomes based rebates that cap net cost per treated patient.
  22. ▲ LH Labcorp — impact +7 · confidence low · horizon quarters · 3rd order
    Genetic testing volumes rise as physicians screen more children for cholestatic mutations that now qualify for approved treatment.
    Chain: treatable disease prompts earlier genetic workup → pediatric hepatologists order more sequencing panels → reference lab test volumes increase → Labcorp diagnostics revenue rises modestly
    What would break the call: Payers restrict reimbursement for broad genetic panels in suspected cholestasis, capping test volume.
  23. ▼ UNH UnitedHealth — impact -6 · confidence low · horizon quarters · 2nd order
    UnitedHealth takes incremental pharmacy claims cost when label expansion enlarges the eligible population for an expensive chronic drug.
    Chain: expanded label adds eligible insured patients → Optum Rx processes more high cost claims → pharmacy benefit cost per member rises → UnitedHealth medical cost ratio edges higher
    What would break the call: Optum secures a deep rebate or exclusive dispensing agreement that offsets the added claims cost.
  24. ▼ TEVA Teva — impact -5 · confidence low · horizon quarters
    Generic ursodiol and rifampin volumes decline as approved targeted therapy displaces off-label supportive prescribing in cholestatic children.

Sources

More

Related scenarios

Stocks in this scenario

MIRM · TAK · ALNY · NTRA · ILMN · INCY · RARE · VRTX · MDGL · QGEN · TVTX · GILD · XBI · CI · COR · TMDX · MCK · CNC · CVS · IQV · ELV · LH · UNH · TEVA

News events · All scenarios · Pricing · Track record · Methodology · Map your own scenario